Showing results (111-120 of 143) with videos related to
Sort By:
Pageof 15
Clinical Science (London, England : 1979)|August 25, 2011
Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucoseTodd S Perlstein, Robert R Henry, Kieren J Mather, et al.Diabetes, Obesity & Metabolism|December 29, 2017
Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trialJeremy Pettus, Dominic Reeds, Tricia S Cavaiola, et al.Diabetes, Obesity & Metabolism|September 15, 2017
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trialLawrence A Leiter, Bertrand Cariou, Dirk Müller-Wieland, et al.Diabetes, Obesity & Metabolism|February 14, 2018
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trialKausik K Ray, Lawrence A Leiter, Dirk Müller-Wieland, et al.Cardiovascular Diabetology|May 27, 2017
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular riskDirk Müller-Wieland, Lawrence A Leiter, Bertrand Cariou, et al.Metabolism: Clinical and Experimental|October 8, 2017
Circulating ApoJ is closely associated with insulin resistance in human subjectsJi A Seo, Min-Cheol Kang, Theodore P Ciaraldi, et al.American Heart Journal|September 11, 2013
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trialA Michael Lincoff, Jean-Claude Tardif, Bruce Neal, et al.Journal of the American College of Cardiology|September 1, 2004
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitusMeenakshi A Bhalla, Audrey Chiang, Victoria A Epshteyn, et al.Proceedings of the National Academy of Sciences of the United States of America|December 14, 2012
Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinaseZhao He, Helen H Zhu, Timothy J Bauler, et al.Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 16, 2016
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSISYehuda Handelsman, Robert R Henry, Zachary T Bloomgarden, et al.Pageof 15